Who Will Own the 'God Molecule'?: The Race to Sell 5-MeO-DMT

5-MeO-DMT is drawing intense competition from biotech entrepreneurs as psychedelics move toward regulated pharmaceuticals. The story centers on Amanda Feilding and the Beckley Foundation, then on the Feildings' drug-development company that targets 5-MeO-DMT as a potential “God molecule” medicine, framing the race as both a scientific and a business problem: early advocacy for harm reduction collides with for-profit incentives. The article also grounds the market pitch in the drug’s origins and real-world practice. It covers toad-based sourcing myths versus the extraction method from Sonoran Desert toad toxins, the drug’s typically rapid, intense effects, and major safety concerns including dissociative and panic reactions, flashbacks, potential serotonin toxicity at high doses, and deaths linked to unsafe ceremony facilitation.